Skip to content

Pharminent

cropped-banner_frontpage_2026-07-11-2.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Clinical Data
  • ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come
  • Clinical Data

ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come

BioSpace

Pfizer showcased multiple late-breakers at the American Society of Clinical Oncology's annual conference but its biggest data are expected later this year.

Oncology

Read full story

pharminent June 2, 2026 (Last updated: June 3, 2026)

BioSpace

Pfizer showcased multiple late-breakers at the American Society of Clinical Oncology’s annual conference but its biggest data are expected later this year.

Oncology

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients
Next: ASCO26: In vivo oncology approaches continue to show promise

Related Stories

  • Clinical Data

AstraZeneca, Ionis drug fails big heart disease study in major setback

pharminent July 9, 2026
  • Clinical Data

Roche’s KRAS drug tops its rivals in lung cancer trial

pharminent July 2, 2026
  • Clinical Data

EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s

pharminent July 1, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.